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Diversity in the T cell receptor (TCR) repertoire provides a miniature defense ability for the T cell immune system that may be 
related to tumor initiation and progression. Understanding the T cell immune status of leukemia patients is critical for estab-
lishing specific immunotherapies. Previous studies have reported abnormal TCR repertoires and clonally expanded TCR V T 
cells in chronic myeloid leukemia in chronic phase (CP-CML). In this study, we investigated the distribution and clonality of 
the TCR V repertoire in 4 cases with imatinib-resistant CML in blast crisis (BC-CML) with abelson murine leukemia viral 
oncogene homolog 1 (ABL1) kinase domain mutations (KDMs). Examination of TCR V expression and clonality was per-
formed by reverse transcription-polymerase chain reaction (RT-PCR) and GeneScan analysis. Significantly skewed TCR V 
repertoires were observed in BC-CML patients with different KDMs, and 4 to 8 oligoclonally expanded TCR V subfamilies 
could be identified in each sample. Intriguingly, a relatively highly expanded V9 clone with the same length as complementa-
rity-determining region 3 (CDR3) (139 bp) was found in all three CML patients in lymphoid blast crisis (LBC-CML) who had 
different KDMs, but the clone was not detected in the only CML patient in myeloid blast crisis (MBC-CML). In conclusion, 
restricted TCR V repertoire expression and decreased clone complexity was a general phenomenon observed in the BC-CML 
patients with different KDMs, indicating the T-cell immunodeficiency of these patients. In addition, clonally expanded V9 T 
cell clones may indicate a specific immune response to leukemia-associated antigens in LBC-CML patients. 
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Chronic myeloid leukemia (CML) is a clonal hematopoietic 
stem cell disorder characterized by the translocation 
t(9q34;22q11), which results in the creation of a novel 
BCR-ABL fusion gene with abnormal tyrosine kinase activ-
ity [1,2]. Imatinib mesylate (IM) is a targeted molecular 
drug that serves as frontline therapy for all phases of CML 
for newly diagnosed patients that works by binding to the 
tyrosine kinase domain of BCR-ABL and inhibiting its 
function [3–5]. Although high response rates are observed 
for CML patients who undergo IM treatment, a significant 
number of patients develop primary or acquired resistance 
to IM [1,2]. Clinical resistance to IM for CML patients has 
been attributed to several mechanisms, and the dominant  
mechanism appears to be the acquisition of point mutations 
in the ABL kinase domain (KD) (30%–90% of patients de-
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velop resistance) that lead to altered affinity for IM by the 
BCR-ABL1 protein [6,7]. However, due to IM treatment 
resistance, a proportion of CML patients easily progress to 
blast crisis phase (blastic transformation may be myeloid, 
lymphoid, or undifferentiated/mixed), which is an advanced 
stage of CML disease progression that contributes to  
the expansion of primitive cells and not mature granul- 
ocytes [8–10]. To date, greater than 90 ABL gene mutants 
have been described [6,11]. Different KD mutants confer 
different sensitivities to ABL kinase inhibitors, and the cor-
relation between the imatinib resistance level and frequency 
of mutations has been analyzed in several studies; however, 
the functional importance of these mutants in terms of 
whether certain mutations affect disease progression or the 
immune response remains unclear. 
T cell receptor (TCR) diversity is one of the defining 
characteristics of the adaptive immune system. This diver-
sity is prerequisite for guaranteeing that an organism can 
fight against a universe of foreign antigens and maintain a 
balanced immune status. The human T cell system is esti-
mated to contain approximately 3×1011 cells, which results 
in estimates for TCR  chain diversity for young adults in 
the range of 2×106 to 2×107 cells, and each TCR  chain 
can combine with 25 or more TCR  chains [12,13]. T cell 
clone diversity originates from T cell differentiation in the 
thymus, which is characterized by the formation of the 
complementarity-determining region (CDR) according to 
rearrangement of multiple variable (V), diversity (D), and 
joining (J) gene segments. In addition, the random insertion 
or deletion of nucleotides between gene segments (V-N-D- 
N-J) increase the clonal diversity [14,15]. Specific recogni-
tion of an antigen mediates the clonal expansion of T cells 
expressing a unique TCR V gene of a characteristic CDR3 
size. Examination of CDR3 may reveal the immune re-
sponse characteristics of an individual and identify anti-
gen-specific TCRs. In our previous study, we found that 
restricted use of the TCR V subfamily is a common char-
acteristic of CML patients, and the oligoclonally expanded 
TCR V21 subfamily was detected in 27.6% of CML pa-
tients and 30.8% of Ph+ B-ALL cases, which may be due to 
clonal expansion in response to leukemia-associated anti-
gens, such as the BCR-ABL fusion protein [16,17]. In light 
of these findings from tyrosine kinase inhibitor (TKI) sensi-
tive CML patients, we investigated whether clonal TCR V 
restrictions are detectable and whether different characteris-
tics of the TCR V repertoire distribution pattern could be 
found in IM-resistant BC-CML patients who carry different 
KDMs. 
1  Materials and methods 
1.1  Samples  
After obtaining patient consent, peripheral blood or bone 
marrow from four CML patients who were in blast crisis 
phase (assigned P1 to P4) that had hematologic or cytoge-
netic resistance to imatinib were collected (P3 had AML 
resembling myeloid blast crisis (MBC), and the other three 
patients had B-ALL resembling lymphoid blast crisis 
(LBC)). Different BCR-ABL KDMs were detected in the 
patients, including T315I in patient 1 (P1), E255K in patient 
2 (P2), Y-253F in patient 3 (P3), and F317L combined with 
a S417Y mutation in patient 4 (P4). Mononuclear cells were 
isolated from fresh peripheral blood or bone marrow by 
Ficoll-Hypaque gradient centrifugation. RNA was extracted 
from the samples according to the manufacturer’s recom-
mendations (TRIzol, Gibco, USA). RNA quality was ana-
lyzed in a 1.0% agarose gel stained with ethidium bromide. 
Two micrograms of RNA was reverse transcribed into 
first-strand cDNA with random hexamer primers using the 
reverse transcriptase of the Superscript II Kit (Gibco). 
cDNA quality was confirmed by RT-PCR of the 2 micro-
globulin gene. 
1.2  RT-PCR for TCR V subfamily member amplifica-
tion 
Twenty-four TCR V sense primers and a single TRBC pri-
mer were used in unlabeled PCR for amplification of the 
TCR V subfamily members. Subsequently, runoff PCR 
was performed with fluorescent primers labeled at the 5′ 
end with a FAM (5-Carboxyfluorescein) fluorophore 
(C-FAM) (TIB MOLBIOL GmbH, Germany). PCR was 
performed as described in our previous study [18].  
1.3  GeneScan analysis for TCR V subfamily clonality  
Unlabeled PCR products (2.0 μL) from subfamily members 
with positive expression were subjected to one run off reac-
tion cycle with a fluorophore-labeled C-fam primer.   
The labeled runoff PCR products (2.0 μL) were 
heat-denatured at 94°C for 4 min with 9.5 μL formamide 
(Hi-Di Formamide, ABI, USA) and 0.5 μL Size Standards 
(GENESCAN™-500-LIZ™, Perkin Elmer, ABI).The sam-
ples were then loaded in a 310 POP-4™ gel (Performance 
Optimized Polymer-4, ABI) and resolved by electrophoresis 
using a 310 DNA sequenator (Perkin Elmer, ABI) for size 
and fluorescence intensity determination using GeneScan 
software [18,19]. 
2  Results 
2.1  Skewed expression patterns of the 24 TCR V sub-
family genes in CML patients with ABL KD mutations 
All of the BC-CML patients with a KD mutation had a sig-
nificantly skewed TCR repertoire with 11 to 16 of the 24 
TCR V subfamilies detected in each patient. The CML 
patient with a Y253F mutation in the ABL gene (P3) failed  
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to express most of the TCR V subfamilies as only 11 of the 
24 could be detected. Of all of the detected subfamilies, 
V9, V16, V19 and V21 were commonly expressed in 
all samples, while V1, V2, V4, V5, V6, V8, V15, 
V18, V22 and V23 were expressed in three of the four 
samples, demonstrating a relatively higher frequency. In 
addition, there were three subfamilies(V3, V11 and V20) 
that were not expressed in all samples, and V7, V12 and 
V17 were detected in only one sample. These six subfami-
lies appear to have a relatively lower usage frequency than 
the other subfamilies (Figure 1).  
2.2  Identification of V T cell clonal expansion in dif-
ferent patients  
Based on GeneScan analysis, we found that a small propor-
tion of polyclonal peaks (multi-peaks) were distributed in 
the TCR V subfamilies expressed in each sample, while a 
clonotypic expansion pattern, which includes monoclonality 
(a single-peak pattern), oligoclonality/oligoclonal tendency 
(a high peak together with one or a few lower peaks) and 
biclonality (bi-peaks), were more common patterns for each 
sample, ranging from four to eight clonally expanded sub-
families in each sample. P2 and P3 had a greater number of 
expanded V subfamilies compared with P1 and P4 (Figure 
1), and oligoclonal TCR V5, V8, V9, V18, V19 or 
V23 were identified in two or more CML samples (Figure 
2). Thus, we further compared the CDR3 lengths (the size 
of peaks corresponding to the type of clone in the same 
TCR V subfamily in the detected sample) in the different 
samples. We found that the V9 subfamily was the most 
frequently clonally expanded TCR  family, a clone peak 
similar to the size of CDR3 (139 bp) could be detected in 
three of the four samples (P1, P2 and P4), and the fluores-
cence intensity captured by the DNA sequenator had a rela-
tively high signal compared with most of the other subfami-
lies in each sample (Figure 2C). In addition, the oligoclo-
nally expanded V5, V8, V18, V19 and V23 subfami-
lies could be detected in two samples (Figure 2 A, B, D–F),  
and the CDR3 size in their primary clones appeared to be 
different. However, a similar clone peak could be found 
when comparing the oligoclonal peaks with each peak in the 
multi-peak background of other samples. For example, the 
oligoclonally expanded V8 clone of 270 bp in P3 could 
also be detected in the multi-peak background of P1 and P2 
(Figure 2B). Oligoclonally expanded TCR V4, V6, V10, 
V16, V21 and V22 were each identified in only one 
sample. Additionally, we found the same phenomenon in 
which a similar primary clone was found in some of the V 
subfamilies (Figure 3 A–F) e.g., oligoclonally expanded 
TCR V4 was found in sample P4 with a CDR3 oligoclonal 
peak at 185 bp, while a clone with a similar size as that of 
CDR3 could be found in the multi-peak background of the 
P1 and P2 samples (Figure 3A). 
3  Discussion 
Several studies have shown that skewed TCR V subfamily 
expression is a common characteristic of leukemia pat-  
ients [20,21], and clonally expanded T cells might indicate a 
specific T cell immune response recognizing tumor-specific 
or associated antigens [19,22]. Skewed expression of TCR 
V subfamily members is also a significant characteristic of 
IM-resistant BC-CML patients with KDMs compared with 
healthy donors who express nearly all of the 24 TCR V 
subfamilies [19,23]. The number of completely detectable 
subfamilies (11 to 16) is similar to that found for CML 
(6.89±4.63 TCR V subfamilies), AML (7.58±4.93) and 
B-ALL (7.67±4.66) patients in our previous studies [2,16]. 
This result indicates that BC-CML patients with 
IM-resistant KDMs also have skewed usage of the TCR V 
repertoire. However, BC-CML patients in which 14 or 16 
TCR V subfamilies have been identified appear to have 
more diverse immune responses due to the clonal evolution 
induced by the extra chromosomal abnormalities observed 
in approximately 80% of BC patients e.g., Phchromosome 
duplication, trisomy 8 or 19 and 17p loss [8,24], and this 
requires further investigation. 
 
 
Figure 1 (color online)  The distribution and clonality of the 24 TCR V subfamilies in BC-CML patients with different ABL kinase domain mutations. 
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Figure 2 (color online)  Comparison of the CDR3 clonality and length in the TCR V subfamilies (V5, V8, V9, V18, V19 and V23) in BC-CML 
samples. Oligoclonally expanded T cells could be identified in two or three samples. In some V subfamilies, V clones that are the same size as CDR3 
could be found in either oligoclonally expanded V clones or among polyclones, such as that for V8, which had a 270 bp CDR in patient P3 that could also 
be detected in the multi-peak background of P1 and P2 (B). However, in some cases, the CDR3 size appeared to be relatively different in the same V sub-
family in different samples e.g., V23 (F). 
Clonally expanded T cell repertoires were detected in all 
of the samples in this study, and P2, which has an E255K 
mutation, and P3, which has a Y253F mutation, had eight 
clonally expanded TCR V subfamilies, accounting for 50% 
(8/16) and 73% (8/11) of the detectable subfamilies in each 
sample, respectively. Clonal T cells have previously been 
identified in normal individuals, but overall, these normally 
represent fewer than 5% of the CDR3 profiles in normal 
donors [20,23]. This abnormal TCR repertoire expression 
pattern revealed two patient characteristics. First, the disap-
pearance of the polyclonal pattern found in several subfami-
lies represents a serious decrease in T cell diversity because 
T cell spectra are characterized by a Gaussian distribution 
containing six to eight peaks (polyclonality) for each sub-
family in GeneScan analysis of healthy donors, and this 
pattern represents a repertoire that guarantees sufficiently 
diverse T cell clones that may be used against different an-
tigens. This TCR expression pattern may explain why leu-
kemia patients are more susceptible to virus infection. For 
example, patient No.3 died several days after sample collec-
tion, and her serious immune deficiency status may be a 
reason for her poor outcome. In addition, whether this ab-
normal T cell spectrum pattern was associated with different 
ABL kinase mutations is a question that needs to be an-
swered in future research. Second, highly expressing oligo-
clonal TCR gene patterns have been reported to be associ-
ated with the highly expressed Ph chromosome in relapsed 
CML patients after bone marrow transplantation, and these 
patterns gradually decrease together with disease remission 
after donor lymphocyte infusion, indicating that a specific T 
cell response to antigens might derive from CML-specific 
BCR-ABL translocations or other leukemia-associated anti-
gens [23].We were unable to precisely quantify which clon-
ally expressed subfamily expanded the most; thus, it is dif-
ficult to determine which T cell clone may have expanded 
in response to tumor-associated antigens in different sam-
ples. Moreover, a relatively highly expanded V9 clone 
(semi-quantified by fluorescence intensity) that was the 
same size as CDR3 (139 bp) was found in patients P1, P2 
and P4 who are CML patients with LBC. It appears that 
these V clones may respond to a similar leukemia antigen 
in patients e.g., some leukemia-related antigens were dis-
played in patients with LBC-CML. Previously, we also de-
tected the oligoclonally expanded V9 subfamily (the main 
clone demonstrating a 145 bp CDR3) in a CML patient that 
had Ph-negative ALL and was in the relapsed stage, and this 
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Figure 3 (color online)  Comparison of the CDR3 clonality and size forV4, V6, V10, V16, V21 and V22 in the BC-CML samples. Oligoclonally 
expanded T cells could be identified in only one sample; however, a similar primary clone was found for the same V subfamily members indifferent sam-
ples e.g.,V4. 
oligoclonally expanded subfamily was not observed in the 
CML-CP stage or post chemotherapy when the patient re-
lapsed with ALL [25]; however, the nucleotide sequence of 
V9 clones should be analyzed to determine whether a con-
served CDR3 structure exists with a size similar to CDR3 
(139 or 145 bp) in different samples. 
In conclusion, IM-resistant BC-CML patients containing 
different point mutations in the ABL gene demonstrated T 
cell immunodeficiency in the TCR V repertoire not only in 
the number of absent TCR V subfamilies but also in the 
decreased complexity of the TCR subfamilies expressed. 
The CML patient with MBC who had an E255K mutation 
(P3) had the most serious deficiency in the TCR V reper-
toire, which appears to correspond to the worse clinical sta-
tus of the patient. Whether specific ABL kinase domain 
mutations are associated with the severity of the deficiency 
in the TCR V repertoire requires further studies focusing 
on analyzing the TCR repertoire with larger numbers of 
patients with specific types of KDMs. In addition, different 
numbers of clonotypic expansion patterns were found in all 
of the patients, and there was no identical oligoclonality 
discovered for the same TCR V subfamily in the four pa-
tients; however, the same V9 clone expanded in all three of 
the LBC-CML patients, which may indicate that despite 
T-cell immunodeficiency, BC-CML patients may have the 
ability to specifically respond to leukemia-associated anti-
gens. Furthermore, using high-throughput sequencing tech-
niques to precisely determine the complete competency of 
the immune repertoire will help determine more accurate 
TCR subgroups for tumor antigen recognition and help in 
precisely and individually treating leukemia. On the other 
hand, epigenetic factors are increasingly recognized to play 
causative roles in cancer development as well. Whether 
aberrations of DNA methylation and histone modifications 
in CML cells have influence on the TCR repertoire is an 
interesting question awaiting further investigation [26]. 
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